// App-Quantinova.ai

TPS4157 : A phase II trial of cabozantinib and erlotinib for patients with EGFR and c-MET co-expressing metastatic pancreatic adenocarcinoma.

Researchers

Presenter

  • Olumide B. Gbolahan

Principal Investigators

  • Amikar Sehdev

  • Safi Shahda

  • Susan Perkins

  • Murray Korc

  • Patrick J. Loehrer

  • Bert H. O'Neil

Medical Centers

  • Indiana University School of Medicine, Indianapolis, IN

  • Indiana University, Indianapolis, IN

  • Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

  • Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

  • IU School of Medicine, Indianapolis, IN

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Presenilin 2

  • Epidermal growth factor receptor

Drug/Treatment

  • Cabozantinib

  • Erlotinib hydrochloride

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

Phase

  • II

Study Id's

  • NCT03213626

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved